Patent application number | Description | Published |
20090280202 | Extracts of Aristolochia Longa pomer and uses thereof - Methods of extracting from a part of a variety of the species | 11-12-2009 |
20090311343 | Thiazole Compounds, and Compositions and Methods Using Same - The present invention provides, in part, compounds and compositions including a thiazole moiety, that may be useful, for example, for treating cancers, for example kidney cancer. | 12-17-2009 |
20100112108 | Extracts of Aristolochia Longa pomer and uses thereof - Methods of extracting from a part of a variety of the species | 05-06-2010 |
20100184807 | Methods to inhibit tumor cell growth by using proton pump inhibitors - Methods of treating one or more growth deregulated cells are disclosed: An effective amount of a pharmaceutical composition including a proton pump inhibitor is administered thereby treating a growth deregulated cell outside of the gastric lumen of a subject. | 07-22-2010 |
20120269902 | Thiazole Compounds, and Compositions and Methods Using Same - The present invention provides, in part, compounds and compositions including a thiazole moiety, that may be useful, for example, for treating cancers, for example kidney cancer. | 10-25-2012 |
20120322820 | METHODS TO INHIBIT TUMOR CELL GROWTH BY USING PROTON PUMP INHIBITORS - Methods of treating one or more growth deregulated cells are disclosed. An effective amount of a pharmaceutical composition including a proton pump inhibitor is administered thereby treating a growth deregulated cell outside of the gastric lumen of a subject. | 12-20-2012 |
Patent application number | Description | Published |
20110053864 | Compositions and methods for modulation of cell migration - A peptide includes SEQ ID NO:3, substitution and addition variants thereof which maintain the ability to activate CD44. A complex includes this peptide or an Å6 polypeptide with a CD44 polypeptide. An isolated polypeptide includes the Link region sequence of human CD44, functionally active fragments thereof, substitution variants, and addition variants. A method of treating a disease characterized by aberrant cell migration and/or invasion includes administering to a subject an effective amount of the peptide of SEQ ID NO:3 or an Å6 polypeptide to bind to a CD44 polypeptide and modulate signal transduction activity for a sufficient period of time to treat the disease. Other methods include using the peptide of SEQ ID NO:3 or an Å6 polypeptide for diagnosing, identifying a subpopulation of subjects responsive to treatment, and screening for compounds that bind a CD44 polypeptide. | 03-03-2011 |
20110217233 | MODULATION OF INTRACELLULAR SIGNALING - A method of treating a disease characterized by aberrant cell migration and/or invasion includes administering to a subject an effective amount of the peptide of SEQ ID NO:3, an Å6 polypeptide, or an isolated polypeptide consisting essentially of the Link region of human CD44 as indicated in FIG. | 09-08-2011 |
20130178463 | ENHANCED TRANSBUCCAL DRUG DELIVERY SYSTEM AND COMPOSITIONS - A buccal delivery system is disclosed suitable for delivery of a therapeutic agent to the oral cavity of a patient. The delivery system comprises a matrix for containing and releasing the therapeutic agent into the oral cavity and an alkyl N,N-disubstituted amino acetate in said matrix. A particularly preferred delivery system comprises a matrix containing an effective amount of therapeutic agent together with an alkyl N,N-disubstituted amino acetate, such as dodecyl 2-(N,N-dimethylamino) propionate salt. | 07-11-2013 |
20130209393 | THERAPEUTIC PEPTIDE COMPOSITIONS AND METHODS - Therapeutic peptide compositions comprise a therapeutic peptide, such as insulin, together with an alkyl N,N-disubstituted amino acetate, such as dodecyl 2-(N,N-dimethylamino) propionate. | 08-15-2013 |
20130210766 | COMPOSITIONS OF SMALL MOLECULE THERAPEUTICS - Compositions containing a small molecule therapeutic and an alkyl N,N-disubstituted amino acetate are disclosed. Inclusion of the alkyl N,N-disubstituted amino acetate enhances the pharmacokinetic properties of the small molecule therapeutic. | 08-15-2013 |
20130267562 | ACTIVE ENANTIOMER OF DODECYL 2-(N,N-DIMETHYLAMINO)-PROPIONATE - 2R-dodecyl 2-(N,N dimethylamino)-propionate (R-DDAIP) provides an unexpectedly improved activity in facilitating transport of a pharmaceutically active compound across biological membranes and tissues, compared to S-DDAIP of the same enantiomeric purity, or racemic DDAIP. Purified S-DDAIP is also provided. | 10-10-2013 |
20140170207 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE - The present disclosure provides antimicrobial compounds, compositions comprising such antimicrobial compounds, and methods of their use, in particular, antibacterial compounds and antifungal compounds. In certain aspects, the antimicrobial compounds are effective against pathogens of hospital-acquired infections. In certain aspects, the antimicrobial compounds are effective against pathogens that are resistant to antibiotics. The antimicrobial compounds can be used in antibacterial compositions, antifungal compositions, antiseptic compositions and disinfectant compositions. The antimicrobial compounds can be used as adjuncts in antibacterial compositions and antifungal compositions. | 06-19-2014 |
20140200274 | METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE - In various embodiments, methods and compositions for treating Raynaud's disease and Raynaud's phenomenon are provided. Topical administration of a semisolid composition comprising a prostaglandin E1 compound provides the desired relief of the Raynaud's disease or Raynaud's phenomenon without the possible complications of systemic administration. The semisolid composition can be administered as needed, or in a regimen of several doses per day. | 07-17-2014 |
20140350482 | RECONSTITUTION DEVICE - The present invention relates to methods for reconstituting and relates to reconstitution devices suitable for reconstituting many different materials. Furthermore, the present invention includes methods of treatment and methods of use related to a reconstitution device or apparatus. Some embodiments are suitable for reconstituting small amounts of a pharmaceutical compositions and using the pharmaceutical composition for the treatment of sexual dysfunction. | 11-27-2014 |
20140357713 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE - The present disclosure provides antimicrobial compounds, compositions comprising such antimicrobial compounds, and methods of their use, in particular, antibacterial compounds and antifungal compounds. In certain aspects, the antimicrobial compounds are effective against pathogens of hospital-acquired infections. In certain aspects, the antimicrobial compounds are effective against pathogens that are resistant to antibiotics. The antimicrobial compounds can be used in antibacterial compositions, antifungal compositions, antiseptic compositions and disinfectant compositions. The antimicrobial compounds can be used as adjuncts in antibacterial compositions and antifungal compositions. | 12-04-2014 |
20150079163 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE - The present disclosure provides antimicrobial compounds, compositions comprising such antimicrobial compounds, and methods of their use, in particular, antibacterial compounds and antifungal compounds. In certain aspects, the antimicrobial compounds are effective against pathogens of hospital-acquired infections. In certain aspects, the antimicrobial compounds are effective against pathogens that are resistant to antibiotics. The antimicrobial compounds can be used in antibacterial compositions, antifungal compositions, antiseptic compositions and disinfectant compositions. The antimicrobial compounds can be used as adjuncts in antibacterial compositions and antifungal compositions. | 03-19-2015 |
Patent application number | Description | Published |
20130185826 | MATERIALS, SYSTEMS, ORGANISMS, AND METHODS FOR ENHANCING ABIOTIC STRESS TOLERANCE, INCREASING BIOMASS, AND/OR ALTERING LIGNIN COMPOSITION - The present disclosure relates, in some embodiments, to materials, systems, organisms, and methods for enhancing abiotic stress tolerance (e.g., cold, salinity, drought, wind), increasing biomass, and/or altering lignin composition in plants. For example, enhancing abiotic stress tolerance may be achieved using a plant-specific family of transcription factors is APETALA2 (AP2), that includes c-repeat binding factor (e.g., CBF1, CBF3) and AP37 nucleic acids and/or polypeptides. In some embodiments, increasing biomass may be achieved by altering expression of gibberellin oxidases (e.g., GA3ox3/GA2ox4) nucleic acids and/or polypeptides. Altering lignin composition may be achieved by suppression of stem-thickening in pith (e.g., STP1) nucleic acids and/or polypeptides. | 07-18-2013 |
20140208462 | COMPOSITIONS, ORGANISMS, SYSTEMS, AND METHODS FOR EXPRESSING A GENE PRODUCT IN PLANTS - The present disclosure relates, in some embodiments, to compositions, organisms, systems, and methods for expressing a gene product in a plant using a expression control sequence (ECS) operable in monocots and/or dicots. For example, (i) an isolated nucleic acid may comprise an ECS (e.g., a sugarcane bacilliform virus promoter) and, optionally, an exogenous nucleic acid (ExNA) operably linked to the ECS; (ii) an expression vector may comprise an ECS; an ExNA; and, optionally, a 3′ termination sequence, wherein the ECS has promoter activity sufficient to express the ExNA in at least one monocot and at least one dicot; (iii) a microorganism, plant cell, or plant may comprise an isolated nucleic acid; (iv) a method for constitutively expressing an ExNA in a plant (e.g., a monocot and/or a dicot) may comprise, contacting an expression vector with the cytosol of a cell of the plant, wherein the expression vector comprises the ExNA and an ECS operable to drive expression of the ExNA; and/or (v) a method of directing constitutive expression of a nucleic acid in a plant (e.g., a monocot and/or a dicot) may comprise transforming the plant with an expression nucleic acid comprising an ECS, an ExNA, and a 3′ termination sequence. | 07-24-2014 |